Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2500
Single User License Price INR 168625
Corporate User License Price USD 7500
Corporate User License Price INR 505875
Site License Price USD 5000
Site License Price INR 337250
Request a Quote

Report Title

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016

Quote Request for License Type
License Type Price  
Single User License USD 2500
Site License USD 5000
Enterprise Wide License USD 7500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016


Quote Request for License Type
License Type Price  
Single User License USD 2500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016



Executive Summary

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016" provides an overview of Relapsed Multiple Myeloma clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsed Multiple Myeloma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9

Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12

Top Five Countries Contributing to Clinical Trials in Central and South America 13

Clinical Trials by G7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 14

Clinical Trials by Phase in G7 Countries 15

Clinical Trials in G7 Countries by Trial Status 16

Clinical Trials by E7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 17

Clinical Trials by Phase in E7 Countries 18

Clinical Trials in E7 Countries by Trial Status 19

Clinical Trials by Phase 20

In Progress Trials by Phase 21

Clinical Trials by Trial Status 22

Clinical Trials by End Point Status 23

Subjects Recruited Over a Period of Time 24

Clinical Trials by Sponsor Type 25

Prominent Sponsors 26

Top Companies Participating in Relapsed Multiple Myeloma Therapeutics Clinical Trials 27

Prominent Drugs 28

Latest Clinical Trials News on Relapsed Multiple Myeloma 29

Jul 28, 2016: AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma 29

Clinical Trial Profile Snapshots 30

Appendix 483

Abbreviations 483

Definitions 483

Research Methodology 484

Secondary Research 484

About GlobalData 485

Contact Us 485

Disclaimer 485

Source 486

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10

Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13

Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2016* 14

Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15

Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16

Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2016* 17

Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18

Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24

Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

GlobalData Methodology 484

List of Tables

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2016* 6

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10

Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13

Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2016* 14

Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15

Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16

Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2016* 17

Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18

Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2016* 20

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24

Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Celgene Corporation

Johnson & Johnson

Novartis AG

Amgen Inc.

Takeda Pharmaceutical Company Limited

Bristol-Myers Squibb Company

AbbVie Inc

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd.

Oncotherapeutics


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand